Neurocrine biosciences presented cahtalyst™ phase 3 pediatric and adult studies, cahtalog™ registry and disease- and glucocorticoid-related comorbidities data in cah at endo 2024

San diego , june 3, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) and diurnal ltd., a neurocrine biosciences company, presented information from its neuroendocrinology pipeline at the endocrine society annual meeting, endo 2024, including primary data just published in the new england journal of medicine from its cahtalyst™ phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency.
NBIX Ratings Summary
NBIX Quant Ranking